Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and glucagon) substituting for the pancreas and facilitating tight euglycemic control in patients with T1DM.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Profil Institut für Stoffwechselforschung GmbH
• Collaborator: European Union
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• Male or female subjects with diabetes mellitus type 1 , as defined by the American Diabetes Association1.

• Age ≥ 18 and ≤ 65 years.

Exclusion Criteria:

• Known or suspected hypersensitivity to trial product(s) or related products.

• Receipt of any investigational medicinal product within 3 months or 5 half-lives of that IMP before randomisation in this trial.